INTRODUCTION
Shh is a key regulator of mammalian development, functioning as both a mitogen and morphogen (Ingham et al., 2011) . Dysregulated Shh signaling results in a wide variety of devastating birth defects and cancers (Cohen, 2012; Nieuwenhuis and Hui, 2005; Traiffort et al., 2010) , so understanding the mechanisms of Shh signaling has been a major goal in developmental and cancer biology. Shh initiates signaling by binding to its receptor Patched (Ptch1). In the absence of ligand, Ptch1 inhibits Smoothened (Smo), a potent pathway activator. Upon Shh binding, Ptch1 no longer represses Smo. Once de-repressed, Smo enhances Gli transcriptional activators and inhibits Gli transcriptional repressors and so alters programs of gene expression.
The mechanisms whereby activated Smo signals to Gli transcription factors are not yet understood. Protein phosphorylation and dephosphorylation regulate multiple physiological functions, and several screens have identified kinases involved in the Shh pathway (Evangelista et al., 2008; Hillman et al., 2011; Jacob et al., 2011; Varjosalo et al., 2008) . However, the role of phosphatases in Shh signaling is largely unexplored. We conducted a small hairpin RNA (shRNA) screen to discover phosphatases in the Shh signaling pathway and identified Eya1 as a positive regulator of this pathway. Eya1 is a phosphotyrosine phosphatase that is mutated in branchio-oto-renal syndrome (Abdelhak et al., 1997; Li et al., 2003; Rayapureddi et al., 2003; Tootle et al., 2003; Xu et al., 1999) . Eya1 dephosphorylates histone variant H2AX and thereby affects DNA repair and cell survival (Cook et al., 2009 ). In addition, catalytically active Eya1 interacts with Six family transcription factors to regulate gene expression during development (Rebay et al., 2005; Tadjuidje and Hegde, 2013) . Both Eya and Six family members have been implicated in tumor proliferation and progression (Christensen et al., 2008; Pandey et al., 2010; Patrick et al., 2013 ).
Here we demonstrate that catalytically active Eya1, and its binding partner Six1, function as transcriptional regulators in Shh signaling pathways. Eya1 and Six1 alter the equipoise between Gli activators and repressors following Shh stimulation, and so determine the ensuing biological response. Therefore Eya1 is required for Shh-regulated proliferation and morphogenesis during hindbrain development. Constitutive activation of the Shh pathway in neural precursors of the hindbrain causes medulloblastoma, a cerebellar cancer that is the most common malignant brain tumor in children (Goodrich et al., 1997) . We show that Eya1 is preferentially expressed in Shh-subtype medulloblastomas and fosters tumor growth. Together these findings identify a critical role for Eya1 and its partner Six1 in promoting Shh-dependent transcription and suggest that Eya1 represents a propitious therapeutic target in medulloblastoma.
RESULTS

Identification of Eya1 as a Regulator of Shh Signal Transduction by RNAi
To identify phosphatases regulating the Shh signaling pathway, we conducted an shRNA screen that encompassed 320 gene targets (Table S1 ). The screen was conducted in ShhLightII 
shRNA Screen to Identify Phosphatases in Shh Signaling
(A) SL2 cells were infected with virus encoding a single shRNA targeting 1 of 320 genes; infected cells were selected with puromycin and stimulated with Shh-conditioned media, SAG, or vehicle control, and Gli-responsive luciferase activity was then measured.
(B) Primary screen average Firefly/Renilla luciferase values confirm Shh pathway activation by Shh and SAG (n = 1,720 wells, *p < 0.01, error bars = SEM).
(C) Replicate Firefly/Renilla luciferase values were averaged for each shRNA and converted to their natural log value.
(D) Primary screen robust Z score results. Genes with two or more hairpins giving results less than À1.5 or greater than 1.5 qualified as hits.
(E) A subset of hits from the primary screen were re-screened. Firefly/Renilla luciferase values were normalized to median Firefly/Renilla luciferase value of negative control shRNAs. Values greater than 4-fold of the median response (above the black line) or less than 25% of the median response qualified as hits. (H) Eya1 shRNA blocks SAG-mediated induction of Gli1 mRNA (n = 5, *p < 0.05, **p < 0.01, error bars = SEM).
(I) Induction of Gli1 protein is blocked by shRNAs targeting Eya1. Actin = loading control.
(J) Induction of Gli1 protein is blocked by an Eya1 shRNA (n = 8,*p < 0.05, **p < 0.01, error bars = SEM).
(legend continued on next page) (SL2) fibroblasts, NIH 3T3 cells stably expressing a Gli-dependent firefly luciferase reporter gene and a constitutive Renilla luciferase gene (Taipale et al., 2000) . To distinguish phosphatases that function in the pathway between Ptch1 and Smo from those that function downstream of Smo, cells were stimulated with full-length Shh ligand, which binds Ptch1, with a direct Smo agonist (SAG) (Chen et al., 2002) , or with vehicle control ( Figure 1A) . Data from the primary screen indicate that both Shh and SAG successfully stimulate the pathway ( Figures 1B  and 1C ). We identified as potential hits those genes for which multiple targeting shRNAs achieved a robust Z score greater than 1.5 ( Figure 1D ; Table S2 ), and we carried out a secondary screen to validate these hits ( Figure 1E ). The secondary, more rigorous screen identified genes for which two or more targeting sequences altered Shh responses by more than 4-fold. Several phosphatases previously implicated in Shh signaling, including catalytic and regulatory subunits of Pp2a, were identified in our screens (Hillman et al., 2011; Nybakken et al., 2005) (Table S3) . None of the phosphatases tested differentially affected signaling initiated by Shh and signaling initiated by SAG, suggesting that the identified phosphatases function downstream of Smo activation (Table S3) . Among the genes recognized in our screen (Table S4) , three phosphatases (Ppm1a, Eya1, and Eya2) are reported to be differentially expressed in Shh-subtype medulloblastoma compared with other medulloblastoma subtypes (Kool et al., 2008; Northcott et al., 2011; Thompson et al., 2006) , suggesting that they are likely to be biologically important for Shh signaling. Analysis of gene expression databases encompassing more than 70 medulloblastomas tumors (Robinson et al., 2012) confirmed that Eya1 expression is consistently higher in Shh subtype medulloblastomas than in other medulloblastoma subtypes ( Figure 1F ). We verified that shRNAs targeting Eya1 and Smo efficiently knock down the target mRNA and that shRNAs targeting Eya1 reduce Eya1 protein levels (Figures S1A-S1C), while shRNAs intended to target Eya2 do not affect Eya2 levels and instead reduce Eya1 mRNA expression (Figures S1D and S1E). We therefore focused our studies on Eya1.
Multiple, validated shRNAs targeting Eya1 clearly inhibit Shh signaling in SL2 cells using several readouts of pathway activation, including SAG-mediated induction of Gli-responsive firefly luciferase ( Figures 1G and S1F ) and induction of the target genes Gli1 and Ptch1 as measured by qPCR and by western blot . Strikingly, Eya1 knockdown inhibits Shh pathway to a similar degree as does Smo knockdown. This is a selective effect on Shh responses, as Eya1 knockdown in SL2 cells does not alter platelet-derived growth factor (PDGF)-induced c-fos expression ( Figure S1J ). Furthermore, under the conditions tested, Eya1 knockdown did not affect cell number overall or alter apoptosis or proliferation as measured by TUNEL staining and by phospho-histone H3 (pH3) staining, respectively (Figures S1K and S1L) . Together these data indicate that Eya1 shRNAs exert a selective effect on Shh-responsive gene induction. Figures 1N, 1O , S1M, and S1N). We verified that endogenous Eya1 is catalytically active in the cells tested, as Eya1 À/À MEFs exhibit increased tyrosine phosphorylation of the substrate H2AX (Cook et al., 2009) , and knockdown of Eya1 increases H2AX phosphorylation in SL2 cells ( Figure S1O ). However, stimulation with a Smo agonist does not alter H2AX expression or phosphorylation status, suggesting that phosphatase activity of Eya1, not changes in H2AX phosphorylation per se, are required for Eya-mediated Shh signaling ( Figure S1P ). The catalytically active phosphatase Eya1 interacts with two DNA-binding proteins, Six and Dach, to regulate multiple developmental processes (Li et al., 2003) . We screened shRNAs targeting diverse members of the Six and Dach protein families in SL2 cells, and found that Six1 is both expressed in these cells and required for Shh pathway activation (Figures 2A and S2A ). Two distinct shRNAs that target Six1 ( Figures 2B-2D ) reduce Gli1 induction in response to SAG to the same extent as Eya1 shRNAs (Figures 2E-2G and S2B); furthermore, simultaneously knocking down Eya1 and Six1 does not additionally impinge on the response to SAG ( Figure 2G ). When introduced into SL2 cells, HA-tagged Eya1 is localized throughout the cell but becomes localized to the nucleus when co-expressed with Six1 ( Figure 2H ). Together, these data are consistent with a model wherein Eya1 and Six1 work together in the nucleus to regulate Shh signal transduction.
Six1 contains a DNA binding domain and binds directly to transcription promoter sites, including the Six4 promoter (Liu et al., 2010a) . However, Six1 does not contain an activation domain, and so catalytically active Eya1 or another co-factor is required to alter gene transcription (Wu et al., 2013) . We analyzed expression of Six4, a known Six1-target gene (Liu et al., 2010b) , in SL2 cells and in MEFs. Stimulation with SAG increases mRNA levels of Six4, and this response depends on Six1, Eya1, and the Shh signaling receptor Smo ( Figure 2I ) but does not require Gli2, the canonical Shh-pathway transcription factor (Figures 2J and S2C) . Chromatin immunoprecipitation (ChIP) studies verified that Six1 interacts with the Six4 promoter in SL2 cells ( Figure 2K ). Taken together, these data indicate that Eya1 cooperates with Six1 to initiate transcription of Shh-dependent genes, including Six4.
Eya1 and Six1 Act in the Shh Signaling Pathway between Smo and Sufu Primary cilia are essential for Shh signaling, and mutants lacking cilia do not respond to pathway stimulation (Goetz and Anderson, 2010 shRNA: Figure 3B ). Eya1 and Six1 shRNAs do not affect the constitutive activation of the pathway induced by Sufu loss or by Gli2 expression ( Figures 3B-3F , S3A, and S3B). Together, these data demonstrate that Eya1 and Six1 function upstream of Sufu and of Gli2 to regulate Shh signaling activity.
Like Eya1 and Six1, Nrp1 and Nrp2 are positive regulators of Shh signaling that mediate signal transduction between Smo and Sufu (Hillman et al., 2011) . Shh pathway activation both (B and C) Six1 shRNAs (Six1-1 and Six1-2) effectively knock down Six1 mRNA (B) (n = 4 or 5, *p < 0.05, error bars = SEM) and reduce Six1 protein levels (C) (actin = loading control). relies on, and increases, Nrp1 expression; however Nrp1 is not a direct target of Gli transcription factors suggesting that Shh might regulate transcription by additional mechanisms other than Gli transcription factors (Hillman et al., 2011; Hochman et al., 2006) .
Knockdown of Eya1 or Six1 reduce Nrp1 and Nrp2 (Figures 4A-4E) in both unstimulated and SAG-stimulated cells, indicating Eya1 and Six1 are required for both basal and Shhinduced Nrp gene expression. Similarly expression of Nrp1 mRNA is reduced in Eya1 À/À MEFs ( Figure 4F ), and catalytically active Eya1, but not inactive D273A Eya1, increases Nrp1 expression following SAG stimulation ( Figure S4 ). In contrast, the transcription factor Gli2 is not required for SAG-dependent Nrp gene induction ( Figure 4G ). Thus transcription factor Six1 and catalytically active co-activator Eya1 rather than Gli transcriptional activators control Shh-regulated Nrp1 expression, thereby conveying signal transduction between Smo and Sufu.
Eya1, Six1, and Nrps Do Not Affect Formation of Gli3 Repressors Shh pathway activity enhances expression and function of Glitranscriptional activators, and concurrently inhibits formation of Gli transcriptional repressors (Blaess et al., 2006; Bok et al., 2007; Wang et al., 2000) . Eya1 and Six1 are required for transcription mediated by Gli-activator species, as assessed by Gli1 gene induction. Similarly, Nrp1 and Nrp2 regulate Gli1 induction in response to pathway stimulation ( Figure 4H ). However, we find that Eya1 and Nrps are not necessary for Shh-dependent inhibition of Gli3 repressors (Gli3R). Eya1 knockdown, or knockdown of Nrp1 and Nrp2, does not alter SAG-induced processing of Gli3 to form the 83kD amino-terminal repressor fragment, Gli3R ( Figures 4I-4L ). In contrast, knockdown of Smo prevents both Gli3R inhibition and SAG-stimulated Gli1 induction. These data indicate that Eya1 and Nrps are required selectively for Smomediated Gli activator functions and not for regulation of Gli3R, and so link Eya1 and Nrps in a pathway that differentially modulates Shh signal transduction.
Eya1 Promotes Shh Signaling in Hindbrain Development and in Tumorigenesis
Eya1 and Six1 are expressed in Shh-responsive cells within the otic vesicle, and Eya1
, and Shh À/À mutants exhibit similar otic vesicle phenotypes (Ozaki et al., 2004; Xu et al., 1999; Zheng et al., 2003; Zou et al., 2006) . To investigate a role for Eya1 in Shh signaling within the auditory system, we analyzed expression of the Shh target genes Gli1, and Ptch1, in Eya1 À/À otic vesicles (Xu et al., 1999 ). These data demonstrate a genetic interaction between Eya1 and Shh signaling in vivo and indicate that Eya1 plays a critical role in Shh-dependent hindbrain development. Shh has a well-recognized role as a mitogen for granule cell precursor proliferation in the developing external granule cell layer (EGL) of the cerebellum (Dahmane and Ruiz i Altaba, 1999; Wallace, 1999; Wechsler-Reya and Scott, 1999) . Eya1 is expressed in the developing cerebellum, and levels decrease during postnatal development (http://www.cdtdb.neuroinf.jp). In the early cerebellum, Eya1 mRNA is evident both in Purkinje Figure 6D ). Importantly, the cerebellar phenotype of Eya1 À/À embryos resembles the phenotype observed at this age with mutations in Gli2 or other mutations that cause loss of Shh activity (Corrales et al., 2004) , with striking reduction in granule cell precursor proliferation as assessed by pH3 and Ki67 staining ( Figures 7A-7C ), without increased cell death ( Figures 7D and 7E ). Eya1 fosters Shh responses during embryonic and postnatal development of the cerebellum, as granule cell precursor proliferation and Gli1, Nrp1, and Ptch1 expression are also dramatically decreased in Eya1 +/À mice at postnatal day 3 ( Figures 7F-7I ). Eya1 acts cell autonomously within granule cell precursors to promote Shh responses, as purified, cultured granule cell precursors that lack Eya1 do not respond to exogenous Shh pathway agonists measured by induction of Gli1, Ptch1, Six4, and Nrp1 ( Figures 7J-7M) . Together these data demonstrate that Eya1 promotes Shh-dependent signaling and proliferation in precursors of the developing cerebellum.
Constitutive activation of Shh signaling in granule cell precursors results in the cerebellar tumor, medulloblastoma (Goodrich et al., 1997; Hallahan et al., 2004; Han et al., 2009) . Heterozygous mutations in Ptch1 in mice and in humans confer a high risk for developing medulloblastoma (Goodrich et al., 1997) . Strikingly, the incidence of medulloblastoma is greatly decreased in mice that are heterozygous for both Ptch1 and Eya1 compared to Ptch1 +/À mice from the same colony ( Figure 7N ), providing in vivo evidence that Eya1 promotes growth of these Shh-pathwaydependent cerebellar tumors. (Li et al., 2003) . In humans, heterozygous mutations in Eya1 and Six1 cause branchio-oto-renal syndrome, in which development of the inner ear, face, and kidneys is perturbed, resulting in deafness and impaired renal function (Kochhar et al., 2007) . Taken together, data that Eya1 facilitates Six1 binding to the Six4 promoter and that Shh-pathway stimulation regulates Six4 expression, indicate that Shh fosters Eya1/Six1-dependent transcription and thereby instigates signal transduc- (Nybakken et al., 2005) .
Eya proteins contain a highly conserved C-terminal domain called the Eya domain, which is necessary for Eya to bind Six. The Eya domain contains a haloacid dehalogenase (HAD) sequence motif that is necessary for tyrosine phosphatase activity (Li et al., 2003; Rayapureddi et al., 2003; Tootle et al., 2003) . Missense Eya mutations that disrupt protein phosphatase activity also impair the function of an Eya-So/Six complex (Mutsuddi et al., 2005; Rayapureddi et al., 2003; Tootle et al., 2003) , but Eya1 dephosphorylation of H2AX does not depend on Six (Cook et al., 2009; Krishnan et al., 2009 ). Thus Eya1 phosphatase can operate either independently or in concert with Six family members. The data presented here indicate that Eya1 acts together with Six1 to mediate Shh signal transduction and demonstrate that Eya1 phosphatase activity is essential for this function.
Eya1 and Six1 Regulate Nrp Gene Expression
A model for the roles of Eya1, Six1, and Nrp1/2 in Shh signal transduction is shown as the graphical abstract. Genetic epistasis experiments indicate that Eya1, Six1, and Nrp1/2 are all positive regulators of Shh transduction, and function in the signaling pathway between activated Smo and Sufu/Gli2. We suggest that a major mechanism by which Eya1 and Six1 regulate Shh signaling is by controlling transcription of Nrp1 and other target genes (Ahmed et al., 2012) . Consistent with a paradigm in which Eya1/Six1 collaborate to directly regulate Nrp expression, Six1 binds to the Nrp1 promoter region by ChIP analysis (Liu et al., 2010b) . Intriguingly, Eya1 and Nrp1/2 regulate Gli activator species but are not involved in generating the Gli3 repressor. These data suggest that the mechanisms regulating Gli activators and repressors diverge from one another subsequent to Smo activation, and that Nrp1/2 function selectively in the branch crucial for Gli activators. Recent studies indicating that expression of Gli activators and repressors exhibit distinct dynamics during development (Junker et al., 2014) accord well with the proposed model. An uncoupling of Gli activator and Gli3R regulation has been reported in mice with a null allele of Arl13b, a small GTPase of the Arf/Arl family (Caspary et al., 2007) . MEFs lacking Arl13b have shorter cilia and abnormal localization of Smo, Gli2, and Gli3 following pathway activation (Caspary et al., 2007; Larkins et al., 2011) . In contrast, absence of Nrp1/2 or of Eya1 do not alter ciliary morphology (Figure 3) and (Hillman et al., 2011) . Although Arl13b preferentially affects Gli activators because of its role in ciliogenesis, it appears that Nrp1/2 functions more directly to liberate Gli activator from sequestration and promote trafficking of Gli activator to nuclear DNA binding sites.
Significance of Eya1 in Shh Signaling in Hindbrain Development and Cancer
We demonstrate that Eya1 is required for Shh signaling in NIH 3T3-derived cells and in MEFs in vitro, and we show that Eya1 promotes Shh signaling in the developing brainstem and hindbrain in vivo. In Eya1 mutants, Gli1 expression is decreased in developing otic vesicle and cerebellum. The genetic interaction between Eya1 and Ptch1 mutations in the otic vesicle, and the phenotypic similarity of the Eya1 mutant cerebellum to mutants with loss of Shh signaling, indicate that Eya1 is critical for multiple biological responses to Shh in the developing hindbrain. However, Eya1 is not uniformly involved in Shhdependent responses. An early function for Shh signaling is patterning of the developing spinal cord, but Eya1 À/À embryos do not exhibit defects in spinal cord patterning ( Figure S7 ). Outside of the nervous system, Eya1 and Six1 function within Shh-producing cells rather than Shh-responsive cells, so Eya1 À/À lung tissue exhibits higher levels of Shh and of Gli1 compared with wild-type counterparts (El-Hashash et al., 2011a , 2011b Lu et al., 2013) . Thus, unlike Ptch1 or Smo, Eya1 is not a core component of the Shh signal transduction pathway but is preferentially involved in a subset of Shh-dependent functions in neural tissues. Overexpression of Eya family members has been reported in many human cancers, often accompanied by misregulation of Six family members (Auvergne et al., 2013; Tadjuidje and Hegde, 2013) . Neuropilins have also been implicated in growth of multiple tumors, including medulloblastoma (Hayden Gephart et al., 2013; Snuderl et al., 2013) . Eya1 is highly expressed in human Shh-subtype medulloblastoma (Figure 2) (Kool et al., 2008; Northcott et al., 2011; Thompson et al., 2006) , and Eya1 promotes medulloblastoma growth both in vitro and in vivo. These data raise the intriguing possibility that targeting Eya1 may provide an effective strategy for treating these cancers. Unlike many transcriptional regulators, Eya1 has enzymatic activity and is therefore a potentially druggable target. In addition, Eya proteins belong to the small HAD family of phosphatases that possess an uncommon catalytic domain. Targeting this infrequent catalytic domain has allowed the development of specific Eya2 phosphatase inhibitors, suggesting that selectively targeting Eya1 may be feasible (Krueger et al., 2013) . Although several promising small molecule inhibitors of Smo can treat basal cell carcinoma and medulloblastoma, not all patients respond consistently to Smo inhibitors (Kool et al., 2014; Metcalfe and de Sauvage, 2011; Rodon et al., 2014) . Selective Eya1 inhibitors may provide an effective alternative approach for blocking Shh signaling and thereby treating these cancers.
EXPERIMENTAL PROCEDURES Animal Studies
All experimental procedures were done in accordance with National Institutes of Health (NIH) guidelines and were approved by the Dana-Farber Cancer Institute's Institutional Animal Care and Use Committee. Eya1 À/À mice were obtained from Pin-Xian Xu (Xu et al., 1999) and Ptch1 +/À mice from Jackson Laboratory (Goodrich et al., 1997) . The morning of the day a vaginal plug was detected was designated E0.5.
Cell Culture and Constructs SL2 cells were obtained from American Type Culture Collection and cultured according to their recommendations. After introduction of pLKO.1 lentiviral shRNAs, cells were selected for infection using puromycin (4 mg/ml), unless otherwise noted. SMB cells were prepared from medulloblastoma tumors of Ptch1 +/À mice. These cells express Shh components and cell viability is dependent on Shh pathway activity (Zhao et al., unpublished data) . Primary granule cell precursors were cultured from E18.5 cerebella as described (Zhou et al., 2007) . SMB cell viability was assayed using CellTiter96 Aqueous One Solution Cell Proliferation Assay (Promega). SL2 cells were transfected using Fugene6 with mouse PiggyBac transposase and a transposon encoding V5-Gli2 or GFP. The coding sequence from full-length Eya1 (Thermo Scientific Clone ID 6848408) was cloned into pcDNA3.1(+)-KozakHAHA, and full-length Eya1 was cloned into pCMV-Sport6. Six1-pCMV-Sport6 was obtained from Open Biosystems (Clone ID 4188451).
MEFs were cultured from E12 Eya1 +/+ and Eya1 À/À littermates, or from Gli2 À/À mice as described (Jozefczuk et al., 2012) . 
Shh Ligand Preparation and Cell Stimulation
293FT cells were transfected with full-length Shh in pcDNA3 using Lipofectamine 2000, and Shh was prepared as described previously (Chan et al., 2009; Witt et al., 2013) . Confluent SL2 cells were stimulated with Shh (300 ng/ml) or SAG (300 nM; Enzo Life Sciences) in DMEM with 0.5% calf serum for 48 to 72 hr. Cells were stimulated with purified PDGF-BB (100 ng/ml for 30 min) in the same media.
shRNA Screen and Analysis pLKO.1 lentiviral shRNAs were from the Broad Institute RNAi Consortium (TRC). SL2 cells were plated in 96-well plates, then each well was infected with a single shRNA lentivirus. shRNAs targeting RFP, GFP, LacZ, and two shRNAs targeting Smo were included on each plate as negative and positive controls, respectively; duplicate plates were tested. Infected cells were selected with 4 mg/ml puromycin, then cells were stimulated with Shh, SAG, or vehicle for 72 hr, then lysed and tested. Luciferase assays were conducted using a dual luciferase reagent (Promega #E1960) kit. shRNAs with a Renilla luciferase value equal to zero were eliminated from analysis. Firefly/Renilla luciferase ratios from duplicate wells were averaged and average Firefly/Renilla luciferase ratios equal to zero were assigned a value of 1 3 10 À6 . We calculated the robust Z score for each shRNA
; median absolute deviation = median {abs[x À median]} 3 1.4826) using the natural logarithm of all values. For the primary screen, genes were considered hits if two or more targeting shRNAs generated a robust Z score less than À1.5 or greater than 1.5 in pathway stimulation conditions. In the secondary screen genes were considered hits if multiple shRNAs resulted in Firefly/Renilla luciferase values less than 25% or greater than 400% of the median value of control shRNAs. Screen analysis was conducted in Microsoft Excel (Microsoft Corporation) and in MATLAB (The MathWorks).
Lentiviral Production
Virus containing media was collected from 293T packaging cells transfected using Fugene6 reagent (Promega) in complete DMEM supplemented with 10% fetal bovine serum or in DMEM/F12 supplemented with B27 (GIBCO). 293T and SL2 cells were transfected using Fugene6 using the protocol from TRC at the RNAi Platform of the Broad Institute of MIT and Harvard at http:// www.broadinstitute.org/rnai/public/.
shRNA Knockdown Lentivirus was generated from pLKO.1 or pCDF (for Eya1 WT and Eya1 D237A; Wu et al., 2013) , lentiviral shRNAs obtained from TRC. SL2 cells were plated in 12-well or 6-well plates, then infected with shRNA lentivirus. Infected cells were selected with 4 mg/ml puromycin, then cells were stimulated with SAG or vehicle (300 ng) for 48 or 72 hr before RNA or protein collection.
Quantitative Real-Time PCR RNA was extracted using Trizol (Invitrogen) according to manufacturer's protocol. Reverse transcription was performed using the cDNA archive kit (Applied Biosystems) according to the manufacturer's specifications. Quantitative real-time RT-PCR was performed using Taqman gene expression assays to assess the expression of Eya1 Mm00438796_m1, Eya2
Mm00803396_m1, Six5 Mm01305439_g1, Nrp1 Mm00435371_m1, and Nrp2 Mm00803099_m1. Values were normalized to gapdh levels.
Western Blotting
Cells were lysed in modified radioimmunoprecipitation assay buffer, and protein lysates were separated by 4% to 12% SDS-PAGE and blotted with primary antibodies. Bands were visualized with secondary antibodies conjugated to horseradish peroxidase (1:10,000: Bio-Rad) and SuperSignal chemiluminescent substrate kit. For western blot quantification, film was scanned using Epson perfection V750 pro scanner and Epson scan software. Backgroundsubtracted band density was measured in ImageJ (NIH) and normalized to actin as a loading control.
Immunohistochemistry and In Situ Hybridization
Immunohistochemistry and in situ hybridization were performed as described (Chan et al., 2009) . For visualization of cilia in dissociated granule cell precursors, dissociated cells were stained with antibodies to acetylated alpha tubulin (Invitrogen #322700) and to gamma tubulin (Sigma #T5192) and imaged on a Leica confocal microscope at 633 with optical zoom (Leica Microsystems). Images were acquired with the Leica Microsystems Application Suite (24.1 build 6384), then processed and analyzed using ImageJ software and Adobe Photoshop 7.0. For pH3 detection, sections were dried at room temperature for 30 to 60 min, rehydrated with PBS 23 for 5 min, and then underwent antigen retrieval in Tris-EDTA antigen retrieval solution (0.005M Tris, 0.001 M EDTA), blocked and permeabilized (3% NGS, 5% BSA, 0.3% Triton X-100) for 1 hr. Tissue was incubated overnight at 4 C with antibody in (3% NGS, 0.3% Triton). Cells in the M phase of the cell cycle were detected using mouse anti-pH3. Primary antibody was washed, secondary antibody was applied, and cells were mounted. pH3-positive cells were detected by immunofluorescence and analyzed using NIS Elements imaging software. Positive cells were manually counted. Sections were collected from three pairs of mutant and wild-type animals, each pair was collected from a unique litter. The detection of apoptotic cells was conducted using DeadEnd Fluorometic TUNEL system staining (Progema, G3250). The percentage of TUNEL-positive cells was calculated using NIS Elements software to manually count TUNEL-positive cells the number DAPI-positive cells. Sections were collected from three pairs of mutant and wild-type animals, each pair was collected from a unique litter.
Antibodies
Antibodies used were Eya1 (Aviva Systems Biology #ARP32434), HA (Millipore #05-904), actin (Cell Signaling #4968), Gli1 (Cell Signaling #2534), Six1 (Abcam #ab84329, #ab86028), Nrp1 (R&D Systems #AF566), Nrp2 (Cell Signaling #3366), Gli2 (Aviva Systems Biology #ARP31885), Gli3 (R&D Systems #AF3690), gamma-tubulin (Sigma #T5192), and acetylated-alpha-tubulin (Invitrogen #322700).
Gene Expression Analysis
Results from Affymetrix arrays of pediatric medulloblastomas (GSE37418) were analyzed. Levels of Eya1 in samples from each of the four tumor subtypes as defined in that study (8 Wnt, 10 Shh, 17 group 3, 39 group 4) were plotted and analyzed in Prism by ANOVA (p < 0.0001).
Methods for Six1 ChIP-qPCR
Approximately 20 million to 80 million SL2 cells were used for a single ChIP experiment. Cells were stimulated with SAG for 3 days, incubated with crosslinking solution (1% formaldehyde, 100 mM NaCl, 1 mM EDTA [pH 8.0], 0.5 mM EGTA [pH 8.0], 50 mM HEPES [pH 7.9]) for 10 min at room temperature. Crosslinking was quenched with 125 mM glycine for 5 min at room temperature, cells were rinsed with cold PBS and resuspended in PBS with protease inhibitors.
To isolate nuclei, cell pellets were lysed in 2 mL of Buffer I (50 mM HEPES KOH [pH 7.5], 140 mM NaCl, 1mM EDTA [pH 8.0], 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 10 mM B-glycerophosphate, 10 mM sodium fluoride, 13 protease inhibitor cocktail, 100 nM okadaic acid) and incubated 10 min at 4 C. Nuclei were then pelleted for 10 min at 4 C at 3,000 rpm. .0], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-laurylsarcosine, 10 mM NaF, 13 protease inhibitor cocktail, 100 nM okadaic acid). Nuclear lysates were sonicated using a Bioruptor sonicator, for a total of 32 cycles. After sonication, samples were centrifuged. After Triton X-100 and SDS were added, samples were incubated for 1 hr at 95 C, then incubated with proteinase K for 30 min at 55 C, purified with the Qiagen PCR purification kit.
Lysates were pre-cleared with 15ul pre-rinsed Protein A Dynabeads in 200 ml TBSTPb (0.01% BSA and 0.2 mM PMSF in 13 TBST). Pre-cleared lysates were incubated with Six1 Abcam antibody coupled to Protein A Dynabeads overnight at 4 C. Beads were then bound to immune complexes, collected, and washed twice each with low-salt buffer and high-salt buffer. 
ACCESSION NUMBERS
The primary data for the shRNA screen reported in this paper (Table S5) 
Supplemental Experimental Procedures
Quantitative Real-Time PCR (qRT-PCR)
RNA was extracted using Trizol (Invitrogen) according to manufacturer's protocol. Reverse Transcription was performed using the cDNA archive kit (Applied Biosystems) according to the manufacturer's specifications.
Quantitative real-time RT-PCR was performed using Taqman gene expression assays to assess the expression of: Eya1 Mm00438796_m1, Eya2
